Symphogen Reports New Data on Anti-EGFR Monoclonal Antibody Mixture

Symphogen to Report New Data on Anti-EGFR Monoclonal Antibody Mixture at ASCO

Symphogen Præsenterer Nye Kliniske Data på Anti-EGFR Antistofblanding på ASCO

Symphogen Expands Previous Private Equity Round, Reaching a Total of € 141 million (USD 185 million)

Symphogen udvider kapitaltilførsel til et samlet provenu på mere end DKK 1 mia.

Symphogen Presents New pan-HER data at Annual AACR Meeting

Symphogen to Present at 31st Annual J.P. Morgan Healthcare Conference

Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA

Symphogen Enters Project Supported by the Danish National Advanced Technology Foundation: Immune Antibody Repertoires in Microdroplets

Symphogen Publishes Final Rozrolimupab (SYM001) Phase 2 Trial Results in ITP in Blood

Symphogen Names Martin Olin Chief Financial Officer and Receives 2nd Tranche from €100 Million 2011 Financing

Symphogen Presents Positive Rozrolimupab (SYM001) Phase 2 Trial Results in ITP at ASH

Symphogen Announces Initiation of Phase 2 Trial of Sym004 EGFR Antibody Mixture in Patients with Squamous Cell Carcinoma of Head and Neck Cancer

Symphogen Presents Preliminary Results from Phase 2 Clinical Trial with Rozrolimupab at the Annual European Hematology Association

Symphogen to Present Rozrolimupab (SYM001) Data at European Hematology Association Meeting

Symphogen to Present Data from the First Clinical Trial with Sym004 at ASCO

SympressT Platform to be presented at ESACT Conference 17 May 2011

Symphogen Welcomes Four New Board Members

Symphogen names new Chief Scientific/Medical and Business Officers

Symphogen Receives US Patent on Lead Cancer Compound Sym004

SYMPHOGEN Raises €100 Million in Private Equity Round

Swedish Orphan Biovitrum returns development rights to Sym001 to Symphogen

Symphogen Receives Milestone Payment from Genentech for Antibody Therapeutic Against Infectious Disease Target

Symphogen and Swedish Orphan Biovitrum receive U.S. orphan drug designation for Rozrolimupab in ITP

Symphogen Announces Publication of Data on the Manufacture of Polyclonal Antibodies Developed Using Sympress™ Technology

Symphogen Issued United States Patent Covering Symplex™ Technology for Antibody Discovery

Symphogen Announces Publication in Molecular Biotechnology of Sympress ™ II Production System Allowing Single-Batch Recombinant Polyclonal Antibody Manufacturing

Symphogen Announces Initiation of Phase 1/2 Trial of Sym004 in Patients with Advanced Solid Tumors in the US

Symphogen Publishes Pre-Clinical Data in Cancer Research Demonstrating Superior Efficacy of Anti–EGFR Monoclonal Antibody Combination Sym004

Symphogen Opens US Operations in Princeton, New Jersey

Symphogen Appoints Jørgen Petersen as Chief Development Officer

Symphogen Appoints Adriann Sax Chief Business Officer

Symphogen and Origen Collaborate to Produce Transgenic Chicken for generation of Fully Human Antibody Therapeutics

Symphogen secures € 33 million financing to support clinical development of antibody products

Symphogen acquires Receptor BioLogix's technology

Symphogen and Meiji Seika Kaisha LTD. Achieve milestone in discovery collaboration for recombinant polyclonal antibody, SYM006

Symphogen to Present Positive Preclinical Data on Sym004 Program for EGF-Receptor Positive Cancers

Biovitrum and Symphogen Report Positive Clinical Results in Novel Rh-immunization Prevention Project

Symphogen-Biovitrum Phase II Clinical Trial Initiated

Symphogen Enters into Strategic Collaboration with Genentech for Antibody Therapeutics

Biovitrum and Symphogen Initiate a Second Clinical Study with a Novel Treatment of Hemolytic Diseases

Symphogen issued patent covering Symplex™ technology for antibody discovery

Biovitrum and Symphogen have Successfully Completed Phase I Clinical Trial with Recombinant Polyclonal Antibody

Biovitrum og Symphogen har færdiggjort succesfyldt fase I klinisk forsøg med et rekombinant polyklonalt antistof

Symphogen IBC Sym003 Press release

Symphogen A/S kåret som Danmarks bedste biotekvirksomhed

Symphogen A/S awarded Best Danish Biotech Company 2007

Symphogen appoints Ian Nicholson to Board of Directors

Symphogen styrker bestyrelse

Symphogen Granted European Patent Covering Use of Polyclonal Antibodies for Allergy Indications

Symphogen and Biovitrum Initiate Phase 1 Clinical Trial with The First Recombinant Polyclonal Antibody to Enter Clinical Evaluation

Symphogen og Biovitrum indleder kliniske studier af ny type lægemiddel

Symphogen receives 5 Million Euro investment from Gilde Healthcare Partners

Symphogen og Meiji indgår samarbejde

Symphogen and Meiji Kaisha enter agreement for recombinant polyclonal antibody product

Symphogen A/S styrker klinisk udvikling

Symphogen appoints Christian Meyer Vice President of Clinical Development and Dr. Henrik Rasmussen to Medical Advisory Board

Symphogen A/S får patent på Sympress™ teknologi til produktion af rekombinante polyklonale antistoffer

Symphogen Issued Patent Covering Sympress™ Technology for Manufacturing Rekombinant Polyclonal Antibodies

Symphogen to evaluate AttSite™ Recombinase for development of manufacturing cell lines

Symphogen appoints Dr Søren Bregenholt Vice President of Project Management

Symphoen udnævner Søren Bregenholt til Vice President of Project Management

Biovitrum and Symphogen Enter Co-development and Commercialization Agreement for Recombinant Polyclonal Antibodies for the treatment of certain blood disorders

Symphogen på vej mod nyt lægemiddel

Kapitaltilførsel på 154 millioner kroner til Symphogen til videre udvikling af rekombinante polyklonale antistoffer

Symphogen A/S and Cambridge Antibody Technology Sign Patent Licensing Agreement

Symphogens Success in Manufacturing Consistent Batches of Polyclonal Antibodies for Clinical Trials Attracts New USD 25 Million Investment